Gossamer Bio(GOSS)2025-03-13 20:01Forward-Looking Statements - The annual report includes forward-looking statements regarding future operations and financial performance, particularly related to seralutinib[15]. - The company does not plan to publicly update or revise forward-looking statements unless required by law[16]. - The report emphasizes the importance of not giving undue weight to estimates and projections due to inherent uncertainties[15]. - The report includes cautionary statements under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995[16]. Clinical Trials and Regulatory Filings - The company anticipates ongoing and planned preclinical studies and clinical trials for seralutinib, with regulatory filings and approvals expected in the near future[15]. Market Data and Estimates - Estimates and statistical data regarding market size and growth are included, but these involve assumptions and limitations[15]. - The report contains industry and market data derived from both internal estimates and independent research[18]. Risks and Uncertainties - The company acknowledges risks and uncertainties that may cause actual results to differ materially from projections[16]. Company Information - The company maintains a website for posting press releases and SEC filings, which are available free of charge[19]. - The company’s trademarks and tradenames are acknowledged, with a note on the convenience of their presentation in the report[17].